Detalhe da pesquisa
1.
Efficacy and safety of switching from dupilumab to upadacitinib versus continuous upadacitinib in moderate-to-severe atopic dermatitis: Results from an open-label extension of the phase 3, randomized, controlled trial (Heads Up).
J Am Acad Dermatol
; 89(3): 478-485, 2023 09.
Artigo
em Inglês
| MEDLINE | ID: mdl-37230366
2.
Adjuvant chemotherapy for stage III colon cancer: relative dose intensity and survival among veterans.
BMC Cancer
; 15: 62, 2015 Feb 18.
Artigo
em Inglês
| MEDLINE | ID: mdl-25884851
3.
Enthesitis and Dactylitis Resolution with Risankizumab for Active Psoriatic Arthritis: Integrated Analysis of the Randomized KEEPsAKE 1 and 2 Trials.
Dermatol Ther (Heidelb)
; 2024 May 13.
Artigo
em Inglês
| MEDLINE | ID: mdl-38739215
4.
Efficacy of risankizumab across subgroups in patients with active psoriatic arthritis: a post hoc integrated analysis of the phase 3 KEEPsAKE 1 and KEEPsAKE 2 randomized controlled trials.
J Dermatolog Treat
; 35(1): 2342383, 2024 Dec.
Artigo
em Inglês
| MEDLINE | ID: mdl-38632977